<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01289223</url>
  </required_header>
  <id_info>
    <org_study_id>BDM3502</org_study_id>
    <secondary_id>2010-022102-41</secondary_id>
    <nct_id>NCT01289223</nct_id>
  </id_info>
  <brief_title>A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.</brief_title>
  <acronym>ROBIN</acronym>
  <official_title>A Randomised, Open Label, Multi-centre, Phase III Study to Investigate the Efficacy of Bendamustine Compared to Treatment of Physician's Choice in the Treatment of Subjects With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma Research Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma Research Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of bendamustine against treatment of physician's choice on&#xD;
      progression-free survival in subjects with indolent B-cell NHL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To test whether bendamustine will improve progression-free survival in subjects with indolent&#xD;
      B-cell NHL that did not respond (stable disease or progressive disease) to rituximab or a&#xD;
      rituximab-containing regimen during or within 6 months of the last rituximab treatment&#xD;
      compared to treatment of physican's choice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Ongoing challenges to successfully recruit the required number of subjects&#xD;
  </why_stopped>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">July 31, 2018</completion_date>
  <primary_completion_date type="Actual">July 31, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>8 cycles of 21 days, then follow up every 3 months</time_frame>
    <description>Screening of 14 days, prior to ramdomisation. 8 cycles of 21 days, then follow up every 3 months after end of last cycle until disease progression, then every 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>8 cycles of 21 days, then follow up every 3 months until progressive disease, then every 6 months for overall survival</time_frame>
    <description>Complete remission (CR)/partial remission (PR), Duration of response (DR), Overall survival (OS), Safety and tolerability, Change in health related quality of life (HRQL) measures</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Indolent B-cell NHL</condition>
  <arm_group>
    <arm_group_label>Treatment of Physicians Choice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Defined as any cancer specific therapy or best supportive care. Treatment should be given according to the label and based upon local institutional medical practice and clinical judgement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bendamustine IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 8 cycles of Bendamustine (120mg/m2 Days 1 and 2, every 21 days (+ 3 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine IV</intervention_name>
    <arm_group_label>Bendamustine IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment of Physicians Choice</intervention_name>
    <description>Defined as any cancer specific therapy or best supportive care. Treatment should be given according to the label and based upon local institutional medical practice and clinical judgement.</description>
    <arm_group_label>Treatment of Physicians Choice</arm_group_label>
    <other_name>Defined as any cancer specific therapy or best supportive care.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Indolent B-cell lymphoma: grades 1-3a follicular, small lymphocytic,&#xD;
             lymphoplasmacytic, and marginal zone lymphoma; stages III-IV, or bulky disease stage&#xD;
             II (i.e. as any single mass &gt; 5 cm in any direction) defined according to WHO&#xD;
             Classification, 2008&#xD;
&#xD;
          2. CT imaging in screening phase (based on local evaluation) showing 2 or more clearly&#xD;
             demarcated lesions with a largest diameter ≥ 1.5 cm, or 1 clearly demarcated lesion&#xD;
             with a largest diameter ≥ 2.0 cm. CT imaging performed at screening will be considered&#xD;
             the baseline image&#xD;
&#xD;
          3. Indolent B-cell NHL that remains stable or unresponsive during or within 6 months of&#xD;
             treatment with rituximab or a rituximab-containing regimen:&#xD;
&#xD;
               -  Maintaining stable disease or failure to achieve PR to rituximab-based therapy.&#xD;
                  (CT imaging will support this finding, and will be performed at least 30 days&#xD;
                  after the last dose of rituximab-based therapy) or,&#xD;
&#xD;
               -  Disease progression while on rituximab-based therapy (e.g., includes 4 weekly&#xD;
                  courses of rituximab given at 6 week intervals) or,&#xD;
&#xD;
               -  Disease progression in subjects with stable disease or better response to&#xD;
                  rituximab-based therapy &lt; 6 months of the last dose of rituximab Note: Subjects&#xD;
                  must have received at least 4 infusions of rituximab (either as monotherapy or in&#xD;
                  combination with any chemotherapy).&#xD;
&#xD;
          4. Screening laboratory values:&#xD;
&#xD;
               -  Platelets ≥ 75,000/µL (7 x 109 cells/L)&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1,000/µL (1.0 x 109 cells/L)&#xD;
&#xD;
               -  ALT, AST and alkaline phosphatase ≤ 2.5 ULN and total bilirubin ≤ 1.5 xULN&#xD;
                  (isolated predominantly indirect hyperbilirubinaemia due to Gilbert's syndrome is&#xD;
                  acceptable for inclusion)&#xD;
&#xD;
          5. ECOG Performance Status of 0, 1, or 2&#xD;
&#xD;
          6. Age ≥ 18 years&#xD;
&#xD;
          7. Life expectancy of at least 3 months&#xD;
&#xD;
          8. Signed written informed consent prior to performing any study-specific procedures&#xD;
&#xD;
        Main exclusion criteria:&#xD;
&#xD;
          1. Grade 3b follicular lymphoma or evidence that the indolent lymphoma has transformed to&#xD;
             aggressive lymphoma as verified by biopsy confirmation [e.g. constitutional symptoms,&#xD;
             poor performance status, fast growing tumour or increasing lactate dehydrogenase (LDH)&#xD;
             level]&#xD;
&#xD;
          2. Previous allogeneic stem cell transplant&#xD;
&#xD;
          3. Previous external beam radiation therapy to the pelvis. Previous external beam&#xD;
             radiation therapy for bony disease to the cranium, mediastinum, and axilla or to more&#xD;
             than 3 vertebral bodies&#xD;
&#xD;
          4. More than 10 mg prednisolone daily at the time of randomisation&#xD;
&#xD;
          5. Prior bendamustine treatment within 1 year of randomisation not resulting in a CR or&#xD;
             PR for at least 6 months&#xD;
&#xD;
          6. Known CNS involvement of indolent lymphoma&#xD;
&#xD;
          7. Other past or current malignancy. Subjects who have been free of malignancy for at&#xD;
             least 5 years, or have a history of definitively treated non-melanoma skin cancer, or&#xD;
             successfully treated in situ carcinoma, are eligible&#xD;
&#xD;
          8. Chronic or current active infectious disease requiring systemic antibiotics,&#xD;
             antifungal, or antiviral treatment such as, but not limited to, chronic renal&#xD;
             infection, chronic chest infection with bronchiectasis, tuberculosis and active&#xD;
             Hepatitis C&#xD;
&#xD;
          9. Clinically significant cardiac disease including unstable angina, acute myocardial&#xD;
             infarction within 6 months of screening, congestive heart failure, and arrhythmia&#xD;
             requiring therapy, with the exception of extrasystoles or minor conduction&#xD;
             abnormalities. Subjects with well controlled congestive heart failure and atrial&#xD;
             arrhythmias need not be excluded but should be discussed with the study Medical&#xD;
             Monitor&#xD;
&#xD;
         10. Significant concurrent, uncontrolled medical condition including, but not limited to,&#xD;
             renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, neurological,&#xD;
             cerebral or psychiatric disease&#xD;
&#xD;
         11. History of significant cerebrovascular disease or event with significant symptoms or&#xD;
             sequelae&#xD;
&#xD;
         12. Current active liver or biliary disease (with the exception of Gilbert's syndrome or&#xD;
             asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease&#xD;
             per investigator assessment)&#xD;
&#xD;
         13. Jaundice&#xD;
&#xD;
         14. Known HIV, Hepatitis B or Hepatitis C positive&#xD;
&#xD;
         15. Creatinine clearance ≤ 10 mL/min (measured or estimated using Cockcroft and Gault&#xD;
             equation)&#xD;
&#xD;
         16. Treatment with any known non-marketed drug substance or experimental therapy within&#xD;
             5-terminal half-lives or 4 weeks prior to screening, whichever is longer or currently&#xD;
             participating in any other interventional clinical study unless the sole purpose of&#xD;
             the study is for collection of survival data&#xD;
&#xD;
         17. Known or suspected inability to comply with study protocol&#xD;
&#xD;
         18. Lactating women, women with a positive pregnancy test at screening or women (of&#xD;
             childbearing potential) as well as men with partners of childbearing potential, who&#xD;
             are not willing to use adequate contraception from study start through last treatment&#xD;
             dose and for 6 months following cessation of treatment. Female contraception must be&#xD;
             individually recommended by an expert. Adequate contraception is defined as&#xD;
             abstinence, oral contraceptive, either combined or progestogen alone, injectable&#xD;
             progestogen, implants of levonorgestrel, estrogenic vaginal ring, percutaneous&#xD;
             contraceptive patches, intrauterine device (IUD) or intrauterine system (IUS), male&#xD;
             partner sterilization (vasectomy with documentation of azoospermia) prior to the&#xD;
             female subject's entry into the study, and this male is the sole partner for that&#xD;
             subject, or double barrier method: condom and an occlusive cap (diaphragm or&#xD;
             cervical/vault caps) with a vaginal spermicidal agent&#xD;
             (foam/gel/film/cream/suppository).&#xD;
&#xD;
        20.Major surgery less than 30 days prior to start of treatment. 21.Known hypersensitivity&#xD;
        to the active substance or any excipients that cannot be controlled by appropriate&#xD;
        pre-medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>QLD 4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Ludmila Demitrovicova</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Slovakia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>February 2, 2011</study_first_submitted>
  <study_first_submitted_qc>February 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2011</study_first_posted>
  <last_update_submitted>August 30, 2018</last_update_submitted>
  <last_update_submitted_qc>August 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Indolent B-cell NHL, bendamustine, rituximab, progression-free survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

